Cidara Therapeutics Inc.
Cidara Therapeutics Increases Authorized Share Count
Summary
Cidara Therapeutics, Inc. announced that its stockholders approved an amendment to increase the authorized number of shares of Common Stock from 50,000,000 shares to 100,000,000 shares at the 2025 Annual Meeting of Stockholders. The meeting also saw approval of amendments to the 2024 Equity Incentive Plan and the ratification of the appointment of Ernst & Young LLP as the independent registered public accounting firm. Stockholders also approved, on an advisory basis, the compensation of the company's named executive officers.
Profitelligence Alerts
Get alerts for CDTX
Be first to know when Cidara Therapeutics Inc. files with the SEC.
Filing Categories
Exhibits (2)
Advertisement
About Cidara Therapeutics Inc.
Cidara Therapeutics Inc. is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel anti-infectives and immunotherapies. Its primary function involves addressing unmet medical needs in the treatment of serious infectious diseases and immune-based conditions. Emphasizing innovation, Cidara Therapeutics is known for its pioneering Cloudbreak platform, which integrates potent drug conjugates designed to address life-threatening bacterial, viral, and fungal infections. The asset prominently impacts the biotechnology and pharmaceutical sectors, endeavoring to transform standard infection treatments with its advanced therapeutic solutions. Cidara's pipeline includes the development of new antifungal agents like rezafungin, aimed at treating invasive fungal infections that significantly affect immunocompromised patients. With its strategic focus, Cidara Therapeutics plays a critical role in the emerging markets of antimicrobial resistance and immunotherapy. Positioned within the healthcare industry, Cidara's contributions hold significant potential to alter existing therapies and specialize in meeting complex medical challenges, reinforcing the broader landscape of pharmaceutical advancements and patient care strategies.
Official SEC Documents
Advertisement